Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean

Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of cou...

Full description

Autores:
De la Hoz Restrepo, Fernando
Alvis Guzman, Nelson
De la Hoz Gomez, Alejandro
Ruiz, Cuauhtémoc
Tipo de recurso:
Article of journal
Fecha de publicación:
2017
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
eng
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/4721
Acceso en línea:
http://hdl.handle.net/11323/4721
https://repositorio.cuc.edu.co/
Palabra clave:
Papillomavirus vaccines
Health policy
Health services research
Program evaluation
Immunization programs
West Indies
Latin America
Vacunas contra el virus del papiloma
Política de salud
Investigación en servicios de salud
Programa de evaluación
Programas de inmunizacion
Indias Occidentales
América latina
Rights
openAccess
License
Attribution-NonCommercial-ShareAlike 4.0 International
id RCUC2_4c97535329f7f46da82050dd64b8cd38
oai_identifier_str oai:repositorio.cuc.edu.co:11323/4721
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.spa.fl_str_mv Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
dc.title.translated.spa.fl_str_mv Políticas y procesos para el humano. vacunación contra el virus del papiloma en latín América y el caribe
title Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
spellingShingle Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
Papillomavirus vaccines
Health policy
Health services research
Program evaluation
Immunization programs
West Indies
Latin America
Vacunas contra el virus del papiloma
Política de salud
Investigación en servicios de salud
Programa de evaluación
Programas de inmunizacion
Indias Occidentales
América latina
title_short Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
title_full Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
title_fullStr Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
title_full_unstemmed Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
title_sort Policies and processes for human papillomavirus vaccination in Latin America and the Caribbean
dc.creator.fl_str_mv De la Hoz Restrepo, Fernando
Alvis Guzman, Nelson
De la Hoz Gomez, Alejandro
Ruiz, Cuauhtémoc
dc.contributor.author.spa.fl_str_mv De la Hoz Restrepo, Fernando
Alvis Guzman, Nelson
De la Hoz Gomez, Alejandro
Ruiz, Cuauhtémoc
dc.subject.spa.fl_str_mv Papillomavirus vaccines
Health policy
Health services research
Program evaluation
Immunization programs
West Indies
Latin America
Vacunas contra el virus del papiloma
Política de salud
Investigación en servicios de salud
Programa de evaluación
Programas de inmunizacion
Indias Occidentales
América latina
topic Papillomavirus vaccines
Health policy
Health services research
Program evaluation
Immunization programs
West Indies
Latin America
Vacunas contra el virus del papiloma
Política de salud
Investigación en servicios de salud
Programa de evaluación
Programas de inmunizacion
Indias Occidentales
América latina
description Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of countries in Latin America and the Caribbean (LAC). Methods. We reviewed national and regional sources of information to identify LAC countries with and without universal HPV vaccination, along with the year of introduction, type of HPV vaccine, vaccination scheme, age groups targeted, and coverage level reached. Incidence rates of cervical cancer were compared across countries with and without an HPV vaccination program, in order to identify inequities in access to HPV vaccines. Results. So far, 10 LAC countries have supplied data on their vaccination policies and vaccination coverage rates to the Pan America Health Organization. The majority of those 10 started their vaccination programs using quadrivalent vaccine. Only Chile, Ecuador, and Mexico started their programs using a two-dose scheme. However, by the end of 2016, most of the other countries had switched from a three-dose to a two-dose scheme. Different age groups are targeted in the various programs. Some countries vaccinate one-year birth cohorts, while others vaccinate multiple-year birth cohorts. By the end of 2014, coverage with at least two doses ranged from a low of 2% to a high of 86%. With the exception of Venezuela, the LAC countries with the largest populations introduced universal HPV vaccination between 2010 and 2014. Despite the progress that has occurred in some LAC countries, there are still 10 LAC nations with cervical cancer rates above the LAC average (21.2 cases per 100 000) that have not introduced an HPV vaccine in their EPI. Conclusions. With several key adjustments, HPV vaccination programs across Latin America and the Caribbean could be substantially strengthened. Ongoing monitoring of HPV infection outcomes is needed in order to assess the impact of different vaccination policies.
publishDate 2017
dc.date.issued.none.fl_str_mv 2017
dc.date.accessioned.none.fl_str_mv 2019-05-27T14:25:24Z
dc.date.available.none.fl_str_mv 2019-05-27T14:25:24Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_6501
status_str acceptedVersion
dc.identifier.uri.spa.fl_str_mv http://hdl.handle.net/11323/4721
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
url http://hdl.handle.net/11323/4721
https://repositorio.cuc.edu.co/
identifier_str_mv Corporación Universidad de la Costa
REDICUC - Repositorio CUC
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartof.spa.fl_str_mv doi: 10.26633/RPSP.2017.124.
dc.relation.references.spa.fl_str_mv 1. Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. 2. Muñoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24S3:S3/1-S3/10. 3. Denny L, Quinn M, Sankaranayanan R. Screening for cervical cancer in developing countries. Vaccine. 2006;24S3:S3/71- S3/77. 4. Centers for Disease Control and Prevention. Progress towards implementation of human papillomavirus vaccination – the Americas 2006–2010. MMWR. 2011;60(40): 1382–4. 5. Petrosky E, Bocchini J, Hariri S, Chesson H, Curtis R, Saraiya M, et al. Use of a 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR 2015; 64:300–4 6. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465–92. 7. Pan American Health Organization. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article& id=9394%3A2014-80percent-adolescentes-americas-vacuna-vph-brasil&catid=740%3Anews-pressreleases&Itemid=1926&lang=en. Accessed 26 February 2016. 8. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4: e453–63. 9. Drolet M, Benard E, Boily M, Ali H, Baandrup L, Bauer H, et al. Population level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015;15:565–80. 10. Stoto M, Cosler S. Evaluation of public health interventions. In: Lloyd F, Morrow C, Mays G, eds. Public health administration: principles for population-based management. 2nd edition. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2007: 495–544. Available from: file:///C:/Users/docisp/Downloads/ Evaluation_of_Public_Health_Interventions%20(2).pdf. Accessed 26 February 2016. 11. Sabin Vaccine Institute. Human papillomavirus (HPV) and related burden of disease in Latin American and the Caribbean. January 2009. Available from: http:// www.sabin.org/updates/resources/human-papillomavirus-hpv-and-related -burdendisease-latin-america-and-caribbean Accessed 8 March 2016. 12. Economic Commission for Latin America and the Caribbean. Demographic bulletin. Latin America and Caribbean. Population estimation and projections. 1950–2050. Available from: http://www.cepal.org/ publicaciones/xml/7/14347/lcg2225.pdf Accessed 26 February 2016. 13. Ministerio de Salud de Argentina. Manual del vacunador 2017. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000926cnt-2016– 12_lineamientos-VPH.pdf Accessed 2 June 2017. 14. Ministério da Saude. Nota informativa sobre mudanças no calendário nacional de vacinação para o ano de 2017. Available from: http://portalarquivos.saude. gov.br/images/pdf/2016/outubro/20/ Nota-Informativa-311-CalendarioNacional-de-Vacinacao-2017.pdf Accessed 2 June 2017. 15. Ministerio de Salud de Chile. Vacunación contra el virus del papiloma humano. Available from: http://web.minsal.cl/vacunacion-contra-el-virus-del-papiloma-humano/ Accessed 2 June 2017. 16. Ministerio de Salud de Panamá. MINSA lanza vacuna contra Virus del Papiloma Humano (VPH) en niños. Available from: http://www.minsa.gob.pa/noticia/minsa-lanza-vacuna-contra-virus-del-papiloma-humano-vph-en-ninos Accessed 2 June 2017. 17. Ministerio de Salud del Perú. Plan de Salud Escolar: más de 475 mil niñas serán vacunadas contra el Virus de Papiloma Humano. 17 March 2015. Available from: http://www.minsa. gob.pe/?op=51&nota=16252 Accessed 14 March 2016. 18. Ministerio de Salud del Perú. Minsa promueve vacuna que protege de cuatro tipos de Virus de Papiloma Humano (VPH) para niñas del quinto y sexto grado. Available from: http://www.minsa.gob. pe/?op=51&nota=20909 Accessed 14 July 2017. 19. Organización Panamericana de la Salud/ Uruguay. MSP inició vacunación contra HPV en adolescentes para prevenir cáncer de cuello de útero. Available from: http://www. paho.org/uru/index.php?option=com_ content&view=article&id=672:msp-iniciovacunacion-contra-hpv-adolescentesprevenir-cancer-cuello-utero-&Itemid=340 Accessed 14 March 2016. 20. El Observador. Vacuna contra el VPH obligatoria para niñas desde el año que viene. 29 September 2016. Available from: http://www.elobservador.com. uy/vacuna-contra-el-hpv-obligatoria-ninas-el-ano-que-viene-n978032 Accessed 2 June 2017. 21. Organización Panamericana de la Salud/ Bolivia. Bolivia introduce la vacuna contra el Virus del Papiloma Humano en su esquema nacional de vacunación. Available from: http://www.paho.org/bol/ index.php?option=com_content&view=article&id=1971:bolivia-introduce-lavacuna-contra-el-virus-del-papilomahumano-en-su-esquema-nacional-devacunacion&Itemid=481 Accessed 2 June 2017. 22. Organización Panamericana de la Salud/ República Dominicana. República Dominicana inicia su Semana de Vacunación de las Américas con la introducción de la vacuna contra el VPH. Available from: http://www.paho.org/dor/index. php?option=com_content&view=article&id=2433:republica-dominicana-inicia -su-semana-de-vacunacion-de-las-americas-con-la-introduccion-de-la-vacunacontra-el-vph&Itemid=362 Accessed 2 June 2017. 23. Secretaria de Salud de Honduras. Salud introduce vacuna del Virus del Papiloma Humano (VPH) para niñas de 11 años. Available from: http://www. salud.gob.hn/web/index.php/component/k2/item/347-salud-introduce-vacuna-del-virus-del-papiloma-humanovph-para-ninas-de-11-anos Accessed 2 June 2017. 24. Bryson M, Duclos P, Jolly A, Cakmak N. A global look at national Immunization Technical Advisory Groups. Vaccine. 2010;28S:A13–A17. 25. Tambini G, Andrus J, Fitzsimmons J, Roses Periago M. Regional immunization programs as a model for strengthening cooperation among nations. Rev Panam Salud Publica. 2006;20(1):54–9. 26. Organización Panamericana de la Salud. Precios del Fondo Rotatorio. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article&id=9561%3A2014-revolving-fund -prices&catid=839%3Arevolving -fund&Itemid=40714&lang=es Accessed 2 June 2017. 27. Palacio-Mejía L, Rangel-Gómez G, Hernández-Avila M, Lazcano-Ponce E. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex. 2003;45(S3):S315–25. 28. Goldie S, Diaz M, Constenla D, Alvis N, Andrus J, Kima SJ. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26S:L59–72. 29. Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1–8. 30. Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Hum Vaccin. 2011;7(12):1374–86. 31. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(19):241–68. 32. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunization schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15(47):pii=19730. 33. Castellsagué X, Ault K, Bosch X, Brown D, Cuzick J, Ferris D, Joura E, et al. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2016;2:61–9 34. Sanchez-Gomez L, Yepez-Lujan F, Hernandez-Florez L. La vacunación contra el virus del papiloma humano en Colombia. Rev Gerenc Polit Salud. 2014; 13(27):5–9
dc.rights.spa.fl_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
http://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.publisher.spa.fl_str_mv Rev Panam Salud Publica
institution Corporación Universidad de la Costa
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstream/11323/4721/1/Policies%20and%20processes%20for%20human.pdf
https://repositorio.cuc.edu.co/bitstream/11323/4721/2/license_rdf
https://repositorio.cuc.edu.co/bitstream/11323/4721/3/license.txt
https://repositorio.cuc.edu.co/bitstream/11323/4721/5/Policies%20and%20processes%20for%20human.pdf.jpg
https://repositorio.cuc.edu.co/bitstream/11323/4721/6/Policies%20and%20processes%20for%20human.pdf.txt
bitstream.checksum.fl_str_mv 3b8246c4f8ac3b8e7c12555dd49b130c
934f4ca17e109e0a05eaeaba504d7ce4
8a4605be74aa9ea9d79846c1fba20a33
7f79248ca319ecdca5cbf7ae2e7eda7b
7ce2e5231557fa6a48b770c159c9af32
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Universidad de La Costa
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1808400074080780288
spelling De la Hoz Restrepo, Fernandofaff3ab3080754849ee5ba3f448b828bAlvis Guzman, Nelson093499b541cef1cde8faf4c83c4016f1De la Hoz Gomez, Alejandro894db6fc33d78da1ddd242e0df573b56Ruiz, Cuauhtémoc5cf18729a385ba097125b450d37bb9332019-05-27T14:25:24Z2019-05-27T14:25:24Z2017http://hdl.handle.net/11323/4721Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Objectives. Three highly effective vaccines are available to prevent human papillomavirus (HPV) infection, and they have been introduced in many countries around the world. This article describes advances and challenges in introducing HPV vaccines in the Expanded Program of Immunization (EPI) of countries in Latin America and the Caribbean (LAC). Methods. We reviewed national and regional sources of information to identify LAC countries with and without universal HPV vaccination, along with the year of introduction, type of HPV vaccine, vaccination scheme, age groups targeted, and coverage level reached. Incidence rates of cervical cancer were compared across countries with and without an HPV vaccination program, in order to identify inequities in access to HPV vaccines. Results. So far, 10 LAC countries have supplied data on their vaccination policies and vaccination coverage rates to the Pan America Health Organization. The majority of those 10 started their vaccination programs using quadrivalent vaccine. Only Chile, Ecuador, and Mexico started their programs using a two-dose scheme. However, by the end of 2016, most of the other countries had switched from a three-dose to a two-dose scheme. Different age groups are targeted in the various programs. Some countries vaccinate one-year birth cohorts, while others vaccinate multiple-year birth cohorts. By the end of 2014, coverage with at least two doses ranged from a low of 2% to a high of 86%. With the exception of Venezuela, the LAC countries with the largest populations introduced universal HPV vaccination between 2010 and 2014. Despite the progress that has occurred in some LAC countries, there are still 10 LAC nations with cervical cancer rates above the LAC average (21.2 cases per 100 000) that have not introduced an HPV vaccine in their EPI. Conclusions. With several key adjustments, HPV vaccination programs across Latin America and the Caribbean could be substantially strengthened. Ongoing monitoring of HPV infection outcomes is needed in order to assess the impact of different vaccination policies.Los objetivos Hay tres vacunas altamente eficaces disponibles para prevenir la infección del virus del papiloma humano (VPH), y se han introducido en muchos países del mundo. Este artículo describe los avances y desafíos en la introducción de vacunas contra el VPH en el Programa Ampliado de Inmunización (EPI) de los países de América Latina y el Caribe (LAC). Los metodos Revisamos las fuentes nacionales y regionales de información para identificar los países de ALC con y sin la vacunación universal contra el VPH, junto con el año de introducción, el tipo de vacuna contra el VPH, el esquema de vacunación, los grupos de edad seleccionados y el nivel de cobertura alcanzado. Las tasas de incidencia de cáncer cervical se compararon entre países con y sin un programa de vacunación contra el VPH, con el fin de identificar las inequidades en el acceso a las vacunas contra el VPH. Resultados Hasta ahora, 10 países de ALC han proporcionado datos sobre sus políticas de vacunación y tasas de cobertura de vacunación a la Organización Panamericana de la Salud. La mayoría de esos 10 comenzaron sus programas de vacunación utilizando la vacuna cuadrivalente. Solo Chile, Ecuador y México comenzaron sus programas utilizando un esquema de dos dosis. Sin embargo, a finales de 2016, la mayoría de los otros países habían cambiado de un esquema de tres dosis a uno de dos dosis. Diferentes grupos de edad son objetivo en los distintos programas. Algunos países vacunan cohortes de nacimiento de un año, mientras que otros vacunan cohortes de nacimiento de varios años. A finales de 2014, la cobertura con al menos dos dosis oscilaba entre un mínimo del 2% y un máximo del 86%. Con la excepción de Venezuela, los países de ALC con las poblaciones más grandes introdujeron la vacunación universal contra el VPH entre 2010 y 2014. A pesar del progreso que se ha producido en algunos países de ALC, todavía hay 10 países de ALC con tasas de cáncer cervical por encima del promedio de ALC (21,2 casos). por cada 100 000) que no han introducido una vacuna contra el VPH en su EPI. Conclusiones. Con varios ajustes clave, los programas de vacunación contra el VPH en América Latina y el Caribe podrían fortalecerse sustancialmente. El monitoreo continuo de los resultados de la infección por VPH es necesario para evaluar el impacto de las diferentes políticas de vacunación. Políticas de vacunación.engRev Panam Salud Publicadoi: 10.26633/RPSP.2017.124.1. Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. 2. Muñoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L. HPV in the etiology of human cancer. Vaccine. 2006; 24S3:S3/1-S3/10. 3. Denny L, Quinn M, Sankaranayanan R. Screening for cervical cancer in developing countries. Vaccine. 2006;24S3:S3/71- S3/77. 4. Centers for Disease Control and Prevention. Progress towards implementation of human papillomavirus vaccination – the Americas 2006–2010. MMWR. 2011;60(40): 1382–4. 5. Petrosky E, Bocchini J, Hariri S, Chesson H, Curtis R, Saraiya M, et al. Use of a 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. MMWR 2015; 64:300–4 6. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465–92. 7. Pan American Health Organization. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article& id=9394%3A2014-80percent-adolescentes-americas-vacuna-vph-brasil&catid=740%3Anews-pressreleases&Itemid=1926&lang=en. Accessed 26 February 2016. 8. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4: e453–63. 9. Drolet M, Benard E, Boily M, Ali H, Baandrup L, Bauer H, et al. Population level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015;15:565–80. 10. Stoto M, Cosler S. Evaluation of public health interventions. In: Lloyd F, Morrow C, Mays G, eds. Public health administration: principles for population-based management. 2nd edition. Sudbury, Massachusetts: Jones and Bartlett Publishers; 2007: 495–544. Available from: file:///C:/Users/docisp/Downloads/ Evaluation_of_Public_Health_Interventions%20(2).pdf. Accessed 26 February 2016. 11. Sabin Vaccine Institute. Human papillomavirus (HPV) and related burden of disease in Latin American and the Caribbean. January 2009. Available from: http:// www.sabin.org/updates/resources/human-papillomavirus-hpv-and-related -burdendisease-latin-america-and-caribbean Accessed 8 March 2016. 12. Economic Commission for Latin America and the Caribbean. Demographic bulletin. Latin America and Caribbean. Population estimation and projections. 1950–2050. Available from: http://www.cepal.org/ publicaciones/xml/7/14347/lcg2225.pdf Accessed 26 February 2016. 13. Ministerio de Salud de Argentina. Manual del vacunador 2017. Available from: http://www.msal.gob.ar/images/stories/bes/graficos/0000000926cnt-2016– 12_lineamientos-VPH.pdf Accessed 2 June 2017. 14. Ministério da Saude. Nota informativa sobre mudanças no calendário nacional de vacinação para o ano de 2017. Available from: http://portalarquivos.saude. gov.br/images/pdf/2016/outubro/20/ Nota-Informativa-311-CalendarioNacional-de-Vacinacao-2017.pdf Accessed 2 June 2017. 15. Ministerio de Salud de Chile. Vacunación contra el virus del papiloma humano. Available from: http://web.minsal.cl/vacunacion-contra-el-virus-del-papiloma-humano/ Accessed 2 June 2017. 16. Ministerio de Salud de Panamá. MINSA lanza vacuna contra Virus del Papiloma Humano (VPH) en niños. Available from: http://www.minsa.gob.pa/noticia/minsa-lanza-vacuna-contra-virus-del-papiloma-humano-vph-en-ninos Accessed 2 June 2017. 17. Ministerio de Salud del Perú. Plan de Salud Escolar: más de 475 mil niñas serán vacunadas contra el Virus de Papiloma Humano. 17 March 2015. Available from: http://www.minsa. gob.pe/?op=51&nota=16252 Accessed 14 March 2016. 18. Ministerio de Salud del Perú. Minsa promueve vacuna que protege de cuatro tipos de Virus de Papiloma Humano (VPH) para niñas del quinto y sexto grado. Available from: http://www.minsa.gob. pe/?op=51&nota=20909 Accessed 14 July 2017. 19. Organización Panamericana de la Salud/ Uruguay. MSP inició vacunación contra HPV en adolescentes para prevenir cáncer de cuello de útero. Available from: http://www. paho.org/uru/index.php?option=com_ content&view=article&id=672:msp-iniciovacunacion-contra-hpv-adolescentesprevenir-cancer-cuello-utero-&Itemid=340 Accessed 14 March 2016. 20. El Observador. Vacuna contra el VPH obligatoria para niñas desde el año que viene. 29 September 2016. Available from: http://www.elobservador.com. uy/vacuna-contra-el-hpv-obligatoria-ninas-el-ano-que-viene-n978032 Accessed 2 June 2017. 21. Organización Panamericana de la Salud/ Bolivia. Bolivia introduce la vacuna contra el Virus del Papiloma Humano en su esquema nacional de vacunación. Available from: http://www.paho.org/bol/ index.php?option=com_content&view=article&id=1971:bolivia-introduce-lavacuna-contra-el-virus-del-papilomahumano-en-su-esquema-nacional-devacunacion&Itemid=481 Accessed 2 June 2017. 22. Organización Panamericana de la Salud/ República Dominicana. República Dominicana inicia su Semana de Vacunación de las Américas con la introducción de la vacuna contra el VPH. Available from: http://www.paho.org/dor/index. php?option=com_content&view=article&id=2433:republica-dominicana-inicia -su-semana-de-vacunacion-de-las-americas-con-la-introduccion-de-la-vacunacontra-el-vph&Itemid=362 Accessed 2 June 2017. 23. Secretaria de Salud de Honduras. Salud introduce vacuna del Virus del Papiloma Humano (VPH) para niñas de 11 años. Available from: http://www. salud.gob.hn/web/index.php/component/k2/item/347-salud-introduce-vacuna-del-virus-del-papiloma-humanovph-para-ninas-de-11-anos Accessed 2 June 2017. 24. Bryson M, Duclos P, Jolly A, Cakmak N. A global look at national Immunization Technical Advisory Groups. Vaccine. 2010;28S:A13–A17. 25. Tambini G, Andrus J, Fitzsimmons J, Roses Periago M. Regional immunization programs as a model for strengthening cooperation among nations. Rev Panam Salud Publica. 2006;20(1):54–9. 26. Organización Panamericana de la Salud. Precios del Fondo Rotatorio. Available from: http://www.paho.org/hq/index. php?option=com_content&view=article&id=9561%3A2014-revolving-fund -prices&catid=839%3Arevolving -fund&Itemid=40714&lang=es Accessed 2 June 2017. 27. Palacio-Mejía L, Rangel-Gómez G, Hernández-Avila M, Lazcano-Ponce E. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex. 2003;45(S3):S315–25. 28. Goldie S, Diaz M, Constenla D, Alvis N, Andrus J, Kima SJ. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 2008;26S:L59–72. 29. Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103:1–8. 30. Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule. Hum Vaccin. 2011;7(12):1374–86. 31. World Health Organization. Human papillomavirus vaccines: WHO position paper. Wkly Epidemiol Rec. 2017;92(19):241–68. 32. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunization schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill. 2010;15(47):pii=19730. 33. Castellsagué X, Ault K, Bosch X, Brown D, Cuzick J, Ferris D, Joura E, et al. Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. Papillomavirus Res. 2016;2:61–9 34. Sanchez-Gomez L, Yepez-Lujan F, Hernandez-Florez L. La vacunación contra el virus del papiloma humano en Colombia. Rev Gerenc Polit Salud. 2014; 13(27):5–9Attribution-NonCommercial-ShareAlike 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Papillomavirus vaccinesHealth policyHealth services researchProgram evaluationImmunization programsWest IndiesLatin AmericaVacunas contra el virus del papilomaPolítica de saludInvestigación en servicios de saludPrograma de evaluaciónProgramas de inmunizacionIndias OccidentalesAmérica latinaPolicies and processes for human papillomavirus vaccination in Latin America and the CaribbeanPolíticas y procesos para el humano. vacunación contra el virus del papiloma en latín América y el caribeArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersionORIGINALPolicies and processes for human.pdfPolicies and processes for human.pdfapplication/pdf2035134https://repositorio.cuc.edu.co/bitstream/11323/4721/1/Policies%20and%20processes%20for%20human.pdf3b8246c4f8ac3b8e7c12555dd49b130cMD51open accessCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81031https://repositorio.cuc.edu.co/bitstream/11323/4721/2/license_rdf934f4ca17e109e0a05eaeaba504d7ce4MD52open accessLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.cuc.edu.co/bitstream/11323/4721/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53open accessTHUMBNAILPolicies and processes for human.pdf.jpgPolicies and processes for human.pdf.jpgimage/jpeg60435https://repositorio.cuc.edu.co/bitstream/11323/4721/5/Policies%20and%20processes%20for%20human.pdf.jpg7f79248ca319ecdca5cbf7ae2e7eda7bMD55open accessTEXTPolicies and processes for human.pdf.txtPolicies and processes for human.pdf.txttext/plain42828https://repositorio.cuc.edu.co/bitstream/11323/4721/6/Policies%20and%20processes%20for%20human.pdf.txt7ce2e5231557fa6a48b770c159c9af32MD56open access11323/4721oai:repositorio.cuc.edu.co:11323/47212023-12-14 13:03:58.12Attribution-NonCommercial-ShareAlike 4.0 International|||http://creativecommons.org/licenses/by-nc-sa/4.0/open accessRepositorio Universidad de La Costabdigital@metabiblioteca.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